Want to see HK:9989 full AI Analyst Report?
Top Page
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
(9989)
Select Model
Select Model
Rating:56Neutral
Price Target:
HK$4.00
▼(-22.93% Downside)
Action:Reiterated
Date:10/31/26
The score is primarily supported by improved profitability versus 2023, stronger recent cash generation, and moderate leverage. Offsetting this are contracting TTM revenue and margin compression that depress ROE, alongside weak technical trend signals and a very high P/E that makes the stock sensitive to any earnings disappointment (despite a supportive dividend yield).
Positive Factors
Cash Generation
Strong positive operating and free cash flow in 2024–TTM, with TTM FCF up 17.5% and conversion near 0.95x net income, indicates recent earnings are supported by cash. That provides capacity to fund operations and investments without relying entirely on external capital.
Negative Factors
Revenue Contraction
TTM revenue declined about 3.0%, showing that recent business activity is not expanding despite the return to profitability. Continued contraction could limit operating leverage, reduce resources available for development, and make future earnings more dependent on cost control.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash Generation
Strong positive operating and free cash flow in 2024–TTM, with TTM FCF up 17.5% and conversion near 0.95x net income, indicates recent earnings are supported by cash. That provides capacity to fund operations and investments without relying entirely on external capital.
Read all positive factors
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (9989) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$14.42B
Dividend Yield4.22%
Average Volume (3M)625.77K
Price to Earnings (P/E)185.1
Beta (1Y)0.73
Revenue Growth3.10%
EPS Growth-46.64%
CountryHK
Employees2,150
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.05
Shares Outstanding220,094,500
10 Day Avg. Volume326,500
30 Day Avg. Volume625,766
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)0.57
Price to Sales (P/S)1.25
P/FCF Ratio4.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.4
Revenue Forecast (FY)HK$5.79B
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Shenzhen Hepalink Pharmaceutical Group Co., Ltd., founded in 1998 and headquartered in Shenzhen, People's Republic of China, operates as an international pharmaceutical company. It is involved in the development, production, and distribution of a ...
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
63
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.08B | 5.48B | 5.28B | 5.45B | 7.16B | 6.37B |
| Gross Profit | 1.73B | 1.74B | 1.76B | 1.80B | 2.33B | 2.03B |
| EBITDA | 455.12M | 846.59M | 1.20B | ― | 1.37B | 726.64M |
| Net Income | 189.81M | 349.49M | 646.74M | ― | 727.43M | 240.79M |
Balance Sheet | ||||||
| Total Assets | 16.62B | 16.63B | 17.34B | 19.20B | 20.81B | 19.11B |
| Cash, Cash Equivalents and Short-Term Investments | 4.27B | 2.83B | 2.56B | 2.27B | 3.45B | 3.93B |
| Total Debt | 2.86B | 2.11B | 2.98B | 3.78B | 6.46B | 5.65B |
| Total Liabilities | 4.52B | 4.55B | 5.14B | 7.22B | 8.41B | 7.58B |
| Stockholders Equity | 12.04B | 12.03B | 12.15B | 11.91B | 12.31B | 11.41B |
Cash Flow | ||||||
| Free Cash Flow | 1.67B | 1.59B | 1.99B | -46.66M | -979.03M | -200.49M |
| Operating Cash Flow | 1.77B | 1.71B | 2.19B | 398.22M | -756.61M | -6.63M |
| Investing Cash Flow | -1.26B | -872.75M | -415.05M | 1.22B | 249.84M | 719.93M |
| Financing Cash Flow | -461.24M | -1.09B | -2.14B | -1.21B | 329.56M | -501.08M |
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Technical Analysis
Neutral
5.19
Price Trends
4.05
Negative
4.13
Negative
4.48
Negative
Market Momentum
-0.03
Negative
49.72
Neutral
65.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9989, the sentiment is Neutral. The current price of 5.19 is above the 20-day moving average (MA) of 3.89, above the 50-day MA of 4.05, and above the 200-day MA of 4.48, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 49.72 is Neutral, neither overbought nor oversold. The STOCH value of 65.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:9989.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$26.72B | 16.30 | 11.32% | 6.71% | -9.56% | -23.22% | |
68 Neutral | HK$29.12B | 6.18 | 7.92% | 5.17% | 7.94% | 52.83% | |
61 Neutral | HK$23.94B | 13.43 | 8.60% | 3.50% | 14.80% | -2.88% | |
56 Neutral | HK$14.42B | 185.14 | 1.58% | 4.22% | 3.10% | -46.64% | |
56 Neutral | HK$65.63B | 17.04 | 7.14% | 2.73% | 9.88% | 9.30% | |
52 Neutral | HK$6.76B | 18.42 | 5.03% | 1.50% | 29.68% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:9989
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
3.94
-1.40
-26.20%
HK:0867
China Medical System Holdings
9.82
-3.65
-27.10%
HK:1513
Livzon Pharmaceutical Group
23.18
-5.02
-17.81%
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
16.47
-6.58
-28.55%
HK:0460
Sihuan Pharmaceutical Holdings Group
0.73
-0.75
-50.71%
HK:3320
China Resources Pharmaceutical Group Ltd.
4.64
-0.11
-2.26%
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Corporate Events
Shenzhen Hepalink Files Unaudited Third-Quarter 2026 Report in Hong Kong
Oct 29, 2026
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has released its unaudited third quarterly report for the nine months ended September 30, 2026, prepared under PRC Accounting Standards. The disclosure is made in compliance with Hong Kong securitie...
Shenzhen Hepalink reshuffles Hong Kong company secretary and process agent roles
Oct 29, 2026
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has announced changes to its corporate governance roles, with joint company secretary and authorised representative Ms. Chan Sze Ting resigning due to work arrangements and, along with Ms. Wong Wai ...
Hepalink Sets Board Meeting to Approve Third-Quarter Results
Oct 16, 2026
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has scheduled a board meeting for October 29, 2026 to review and approve the group’s third quarterly results for the nine months ended September 30, 2026. The approval and subsequent publicati...
Hepalink Shareholders Back Higher Wealth Management and Bank Credit Limits at 2026 EGM
Sep 22, 2026
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. reported that shareholders approved all resolutions at its first extraordinary general meeting of 2026 held in Shenzhen on September 22. The meeting, which complied with PRC company law and Hong Kon...
Hepalink convenes 2026 EGM to expand wealth management and credit lines
Aug 31, 2026
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has called its first extraordinary general meeting of 2026 for September 22 in Shenzhen, inviting shareholders of its H shares to vote on key financial management resolutions. The meeting will consi...
Hepalink Profit Slumps on Lower Revenue Despite Margin Improvement
Aug 28, 2026
Shenzhen Hepalink Pharmaceutical Group reported interim unaudited revenue of RMB2.56 billion for the six months ended June 30, 2026, an 8.2% decline from a year earlier, while profit attributable to shareholders fell 36.6% to RMB275.3 million. Des...
Hepalink Raises Wealth Management Fund Limit, Trims Guarantee Cap
Aug 28, 2026
Shenzhen Hepalink Pharmaceutical Group plans to raise the cap on its use of internal funds for purchasing wealth management products and managing cash flow from RMB2.5 billion to RMB3.5 billion, effective until its 2026 annual general meeting, to ...
Shenzhen Hepalink Sets Board Meeting to Review Interim Results and Dividend
Aug 14, 2026
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has scheduled a board meeting for August 28, 2026 to review and approve the Group’s interim results for the six months ended June 30, 2026, and to decide on the publication of those results.Th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.